CBER/CDER Oncology Divisions Will Remain Separate, FDA Confirms
Executive Summary
Maintaining separate oncology review teams for drugs and biologics will help to ensure a "smooth" transition in the reorganization of CBER and CDER, Office of New Drugs Deputy Director Sandra Kweder, MD, said Dec. 11
You may also be interested in...
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
CDER “Comprehensive” Reorganization To Follow After CBER-CDER Merger
CDER plans to reorganize under indication-based divisions following the merger between the center for drugs and center for biologics, Office of New Drugs Director John Jenkins, MD, said during the Biotechnology Industry annual meeting in Washington, D.C. June 24